Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Narcolepsy symbols : AXSM save search
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 3.64%
H: 0.35%
C: -7.48%
axs-12 narcolepsy symphony trial therapeutics
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 3.64%
H: 0.35%
C: -7.48%
narcolepsy therapeutics results
Narcolepsy Market Analysis, Market Size, Epidemiology, and Competitive Analysis of Leading Companies Including Takeda, Suven Life Sciences Limited, Axsome Therapeutics, Inc., Avadel, and Others by DelveInsight
Published: 2023-10-03 (Crawled : 21:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.39%
H: 0.0%
C: 0.0%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.66%
H: 2.5%
C: 1.89%
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: -0.82%
H: 5.05%
C: 4.42%
companies life narcolepsy sciences market
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
Published: 2023-09-21 (Crawled : 11:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -1.42%
H: 3.9%
C: 2.86%
day narcolepsy world global therapeutics
Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Published: 2022-05-09 (Crawled : 12:00) - prnewswire.com
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -1.4%
H: 0.61%
C: -4.73%
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -17.99%
H: 1.48%
C: -7.64%
sunosi acquisition narcolepsy therapeutics solriamfetol
Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial of AXS-12 in Narcolepsy
Published: 2021-09-16 (Crawled : 11:20) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: -0.32%
H: 6.3%
C: 3.26%
narcolepsy phase 3 trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.